AstraZeneca PLCAZNNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +23.84% | +7.17% | +11.74% | +11.99% | +4.11% |
| Gross Profit Growth | +25.22% | +8.47% | +11.43% | +18.18% | +1.80% |
| EBITDA Growth | +5.25% | +12.69% | +20.30% | +27.43% | +64.19% |
| Operating Income Growth | +64.99% | +17.95% | +27.75% | +70.13% | +46.27% |
| Net Income Growth | +56.25% | +33.82% | +27.14% | +77.26% | +55.07% |
| EPS Growth | +59.02% | +33.33% | +27.42% | +77.17% | +55.67% |
| EPS Diluted Growth | +57.38% | +33.57% | +26.61% | +76.09% | +54.17% |
| Weighted Average Shares Growth | +0.06% | +0.06% | -0.26% | +0.61% | +0.00% |
| Weighted Average Shares Diluted Growth | +0.06% | +0.06% | -0.06% | +0.06% | +0.00% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +22.14% | +49.36% | +9.76% | +51.76% | -16.41% |
| Free Cash Flow Growth | +36.12% | +272.76% | -39.47% | +119.65% | -29.48% |
| Receivables Growth | +23.44% | +19.67% | +28.25% | +20.70% | +17.00% |
| Inventory Growth | -2.51% | +10.25% | +14.12% | +16.44% | +24.00% |
| Asset Growth | +2.88% | +3.87% | +7.75% | +9.09% | +9.65% |
| Book Value per Share Growth | +4.13% | +9.53% | +13.47% | +12.01% | +19.32% |
| Debt Growth | +5.21% | -8.20% | -2.07% | +3.48% | -1.36% |
| R&D Expense Growth | +52.20% | +13.51% | +17.95% | +17.59% | -17.43% |
| SG&A Expenses Growth | +0.67% | -0.06% | -1.07% | -1.04% | +1.66% |